About Andrew Pearlman
Form D filings for Eumentis Therapeutics from 2020 to 2024 list Andrew Pearlman as director.
Andrew Pearlman first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Andrew Pearlman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Andrew Pearlman works with at each company, as listed on that company's latest Form D.
Eumentis Therapeutics, Inc. · Form D, Jun 26, 2024
MB
Maryann Bryla
Director
JL
James Larrick
Director
RM
Randall Marshall
Executive officer
KP
Kim Patrick
Director
MT
Mark Tepper
President and director